Stockscreener 앱 받기
309.72
2.76%
8.33
시간 외 거래:
310.99
1.27
+0.41%
전일 마감가:
$301.39
열려 있는:
$302.96
하루 거래량:
533.84K
Relative Volume:
0.90
시가총액:
$13.97B
수익:
$2.99B
순이익/손실:
$1.21B
주가수익비율:
12.36
EPS:
25.06
순현금흐름:
$1.13B
1주 성능:
+2.42%
1개월 성능:
+4.81%
6개월 성능:
-16.39%
1년 성능:
-4.29%
1일 변동 폭
$301.30
$310.07
1주일 범위
$292.34
$310.07
52주 변동 폭
$266.98
$417.81
유나이티드 테라퓨틱스 Stock (UTHR) Company Profile
명칭
United Therapeutics Corp
전화
(301) 608-9292
주소
1000 SPRING ST, SILVER SPRING, MD
UTHR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
309.72 | 13.63B | 2.99B | 1.21B | 1.13B | 25.06 |
|
ZTS
Zoetis Inc
|
152.44 | 66.38B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 46.20B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.69 | 42.99B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.21 | 19.04B | 16.54B | -1.64B | 749.00M | -1.45 |
유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2024-02-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-12-05 | 개시 | Goldman | Sell |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-20 | 재확인 | BofA Securities | Underperform |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-02-11 | 개시 | BTIG Research | Neutral |
| 2021-07-14 | 업그레이드 | Argus | Hold → Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-01 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-06-25 | 재확인 | H.C. Wainwright | Neutral |
| 2020-03-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-27 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-01-31 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 개시 | BofA/Merrill | Underperform |
| 2019-08-01 | 업그레이드 | Jefferies | Underperform → Hold |
| 2019-08-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | 업그레이드 | UBS | Sell → Neutral |
| 2019-05-09 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2018-08-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 재확인 | Barclays | Underweight |
| 2018-01-18 | 재개 | Credit Suisse | Underperform |
| 2017-12-27 | 재확인 | Wedbush | Outperform |
| 2017-04-27 | 재확인 | Wedbush | Outperform |
| 2017-03-30 | 개시 | UBS | Sell |
| 2017-03-16 | 개시 | Credit Suisse | Underperform |
모두보기
유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스
United Therapeutics stock price target raised to $415 from $385 at UBS - Investing.com
United Therapeutics stock price target raised to $415 from $385 at UBS By Investing.com - Investing.com South Africa
United Therapeutics’ Promising Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis - TipRanks
United Therapeutics’ Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis: A Potential Game-Changer - The Globe and Mail
Pfizer’s Inclacumab Study: Long-term Safety Insights for Sickle Cell Disease - The Globe and Mail
Should You Be Adding United Therapeutics (NASDAQ:UTHR) To Your Watchlist Today? - 富途牛牛
United Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for IPF Treatment - TipRanks
MannKind (MNKD) Q2 Revenue Rises 6% - The Motley Fool
H.C. Wainwright Lowers PT on United Therapeutics Corporation (UTHR) to $400 From $425, Keeps a Buy Rating - Insider Monkey
United Therapeutics Announces $1B Accelerated Share Repurchase Program. - AInvest
United Therapeutics Second Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
United Therapeutics’ PAH Study Update: Implications for Investors - TipRanks
United Therapeutics Advances in Pulmonary Fibrosis Treatment with Phase 3 Study - TipRanks
United Therapeutics (UTHR) Launches $1B Stock Buyback Program - GuruFocus
United Therapeutics Corporation (NASDAQ:UTHR) Q2 2025 Earnings Call Transcript - Insider Monkey
United Therapeutics stock jumps on $1 billion share repurchase plan - Investing.com
United Therapeutics Launches $1 Bln Stock Buyback - Nasdaq
United Therapeutics Unveils Massive $1B Stock Buyback Plan in Strategic Financial Move - Stock Titan
Pulmonary Arterial Hypertension Drug Market to See Booming - openPR.com
What is the dividend policy of United Therapeutics Corporation stockFree Stock Alerts For Every Investor - Jammu Links News
United Therapeutics Reports Record Q2 2025 Financial Results - The Globe and Mail
BTIG Lowers Liquidia (LQDA) PT to $40, Potential for Yutrepia Launch Remains a Focus - Insider Monkey
United Therapeutics Reports Record Revenue and Growth - TipRanks
United Therapeutics (UTHR) Price Target Lowered by HC Wainwright & Co. | UTHR Stock News - GuruFocus
H.C. Wainwright lowers United Therapeutics stock price target on Tyvaso competition concerns - Investing.com Nigeria
United Therapeutics Corp (UTHR) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic ... By GuruFocus - Investing.com Canada
United Therapeutics: Q2 Earnings Snapshot - Greenwich Time
Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insight - GuruFocus
United Therapeutics’ Phase 3 Study on Inhaled Treprostinil: A Potential Game-Changer for IPF Treatment - TipRanks
United Therapeutics Stock Slides On Q2 Earnings: The Details - 富途牛牛
Earnings call transcript: United Therapeutics Q2 2025 misses EPS, stock drops - Investing.com Canada
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock - Yahoo Finance
Compared to Estimates, United Therapeutics (UTHR) Q2 Earnings: A Look at Key Metrics - Nasdaq
United Therapeutics Q2 2025 slides: Revenue up 12% as Tyvaso drives growth - Investing.com Nigeria
United Therapeutics Logs Growth And Launches Big Buyback - Finimize
United Therapeutics (UTHR) Misses Q2 Earnings Estimates - Yahoo Finance
United Therapeutics misses Q2 earnings expectations By Investing.com - Investing.com South Africa
United Therapeutics misses Q2 earnings expectations - Investing.com
United Therapeutics (NASDAQ:UTHR) Misses Q2 Revenue Estimates - Yahoo Finance
United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results - TradingView
UNITED THERAPEUTICS Corp SEC 10-Q Report - TradingView
United Therapeutics earnings missed by $0.94, revenue fell short of estimates - Investing.com
United Therapeutics Delivers Triple Win: Record $799M Revenue, $1B Buyback, and Major Pipeline Progress - Stock Titan
유나이티드 테라퓨틱스 (UTHR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
유나이티드 테라퓨틱스 주식 (UTHR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Aug 07 '25 |
Sale |
300.00 |
11,000 |
3,299,981 |
36,781 |
2.12%
자본화:
|
볼륨(24시간):